International Journal of Medical Laboratory Research (IJMLR)

CHRONIC LIVER DISEASE: DISTRIBUTION AND BIOMARKERS IMPACTS IN EDO STATE

​

BIG Adejumo, MO Imoroa, FO Oyakhire , GU Ottah, GE Obasuyi, AO Ogbebor

​​

ABSTRACT: Aim - This study aimed to determine the distribution of chronic liver disease, associated risk factors, and its impact on gamma-glutamyl transferase (GGT) activity and alpha-fetoprotein (AFP) levels in Edo State. Method: Sixty participants were enrolled, comprising 30 diagnosed with liver disease and 30 healthy controls. Patients were recruited from Edo Central Hospital, Benin City, while controls were from the general population. Demographic data were collected via questionnaires, and GGT activity and AFP levels were measured using standard methods. Result - Results revealed significantly higher GGT (81.43 ± 23.94 ng/ml) and AFP (105.97 ± 191.44 ng/ml) levels in patients compared to controls (22.76 ± 10.01 ng/ml and 6.40 ± 23.43 ng/ml, respectively). Most patients were aged 40–59 years (50%), predominantly female, married, and employed. A minority (6.7%) reported a family history of liver disease. Conclusion- Elevated GGT and AFP levels in patients indicate possible cellular destruction due to inflammation, which is a significant indication of liver ailment. Public education on healthy lifestyles and routine medical checks is recommended to mitigate liver disease prevalence and impact.

​

Keywords: alpha fetoprotein, gamma glutamyl transferase, biomarkers, chronic hepatitis, Edo State

​

REFERENCES:​​

1. [1]. Allen SE. The liver: Anatomy, Physiology, Disease & Treatment. North Eastern: University Press, USA. 2002

2. [2]. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. Journal of Hepatology. 2013, 58,3:593-608.

3. [3]. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. New England Journal of Medicine 2011;365,2:147-56.

4. [4]. Zhang B, Liu S, Zhou B, Guo L, Li H, Yan J, Zhang W, Yu M, Chen Z, Xu Y, Xiao Y, Ye Q. High serum gamma-glutamyl transpeptidase concentration associates with poor postoperative prognosis of patients with hepatitis B virus-associated intrahepatic cholangiocarcinoma. Annals of Translational Medicine's. 2021;9,1:17

5. [5]. American liver foundation. The Liver Lowdown-Liver Disease: the big picture. March 2017.

6. [6]. Carr BI, Akkiz H, Bag HG, Karaoğullarından U, Yalçın K, Ekin N, Özakyol A, Altıntaş E, Balaban HY, Şimşek H. Serum levels of gamma-glutamyl transpeptidase in relation to HCC human biology and prognosis. Journal of Translational Science 2021, 7, 1000446.

7. [7]. Mulcahy N. FDA Approves First Biomarker-Driven Drug for HCC. Medscape Medical News, FDA Approvals 2019. Available online at https://www.medscape.com/viewarticle/912935. Accessed July 2022.

8. [8]. Genzen, J, Miles, R. Hepatocellular Carcinoma – HCC. ARUP Consult 2019. Available online at https://arupconsult.com/content/hepatocellular-carcinoma?_ga=2.254743051.2056076676.1573304696-1793245273.1560683717. Accessed July 2022.

9. [9]. Grund S. Hepatocellular Carcinoma. MedlinePlus, Medical Encyclopedia 2004 [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/ency/article/000280.htm.

10. [10]. Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Disease. 2020, 7, 308–319.

11. [11]. Szewczuk A, Kuropatwa M, Lang D. Colorimetric method for assay of serum gamma-glutamyltransferase activity with some L-gamma-glutamyl-carboxyanilides. Clinica Chimica Acta. 1988;178,1:35-40.

12. [12]. Conradie JD, Gray R, Mbhele BE. Serum alphafetoprotein determination by enzyme-linked immunosorbent assay. South African Medical Journal 1980;58,4:169-71.

13. [13]. Moon AM, Singal AG, Tapper EB. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clinical Gastroenterology and Hepatology. 2020 ;18,12:2650-2666.

14. [14]. Bagherniya M, Nobili V, Blesso CN, Sahebkar A. Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review. Pharmacological Research. 2018; 130:213-240.

15. [15]. Sajja KC, Mohan DP, Rockey DC. Age and ethnicity in cirrhosis. Journal of Investigative Medicine. 2014 ;62,7:920-6.

16. [16]. Kim WR, Brown RS, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. In: Vol 36 2002: 227–242.

17. [17]. Ratib S, West J, Crooks CJ, Fleming KM. Diagnosis of liver cirrhosis in England, a cohort study, 1998–2009: a comparison with cancer. American Journal Gastroenterology. 2014;109,2:190–198.

18. [18]. Non-alcoholic Fatty Liver Disease Study Group, Lonardo A, Bellentani S. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Digestive and Liver Disease. 2015;47,12:997–1006.

19. [19]. Scaglione S, Kliethermes S, Cao G. The Epidemiology of Cirrhosis in the United States: A Population-based Study. Journal of Clinical Gastroenterology. 2015;49,8:690–696.

20. [20]. Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infectious Disease 2018;18,1:79.

21. [21]. World Health Organization. Global hepatitis report 2017. 2019:2017. Accessed March 6, 2019.

22. [22]. Denniston MM, Jiles, RB.  Drobeniuc, J. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Annal of Internal Medicine. 2014; 160:293-300

23. [23]. Polaris Observatory HCV Collaborators, Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterology and Hepatology. 2017; 2:161-176.

24. [24].  Maisanda BW, Manfred M. Prevalence of Chronic Liver Diseases Caused by HBV and HCV in Nigeria in Comparison with European Countries. Medical Representative Case Studies: 2018, 3:2

25. [25]. Nwokediuko SC, Osuala PC, Uduma UV, Alaneme AK, Onwuka CC, Mesigo C. Pattern of liver disease admissions in a Nigerian tertiary hospital. Nigerian Journal of Clinical Practice 2013 ;16,3:339-42.

26. [26]. Roerecke M, Vafaei A, Hasan OSM, Chrystoja BR, Cruz M, Lee R, Neuman MG, Rehm J. Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology. 2019;114,10:1574-1586.

27. [27]. Rutledge SM, Asgharpour A. Smoking and Liver Disease. Gastroenterol Hepatol (N Y). 2020;16,12:617-625.

28. [28]. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rossob S, Coeberghc JWW, Combere DH, Formana D, Formana F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49,6:1374-1403.

29. [29]. Seleye-Fubara D, Jebbin NJ. Hepatocellular carcinoma in Port Harcourt, Nigeria: Clinicopathologic study of 75 cases. Annals of African Medicine; 2007, 6: 54-57.

30. [30]. Akinyinka OO, Falade AG, Ogunbiyi O, Johnson AO. Hepatocellular carcinoma in Nigerian children. Annals of Tropical Paediatrics:2001; 21: 165-168.

31. [31]. Joo JH, Kim HJ, Park EC, Jang SI. Association between sitting time and non-alcoholic fatty live disease in South Korean population: a cross-sectional study. Lipids Health Dis. 2020;19,1:212.

32. [32]. Silva FQ, Santos FJA, Andrade AP,  Pacheco S D B,  Fischer B,  Pinho J R R,  Lemos J A R,  Oliveira-Filho A B. Hepatitis C virus infection among illicit drug users in an archipelago of the Amazon. Arch Virol. 2018;163,3:617-622.

33. [33]. Zhang Z, Lu M, Geng H, Ying B. Effects of smoking & drinking on serum-GGT levels using physical examination data: a cross-section of NW China. International Journal of General Medicine 2021. 14, 1301-1309.

34. [34]. Teschke R, Rauen J, Neuefeind M, Petrides AS, Strohmeyer G. Alcoholic liver disease associated with increased gamma-glutamyltransferase activities in serum and liver. Adv Exp Med Biol. 1980; 132:647-654.

35. [35]. Wang Y, Cui X, Zhang H, Ding X, Hu D, Song Y, Chen L Xin Y. Elevated Serum Alpha-fetoprotein Levels in Non-alcoholic Steatohepatitis: Possible Molecular Mechanisms and Potential Clinical Significance. Gene expression 2023;22,2:135-140.

36. [36]. Dabeva MD, Laconi E, Oren R, Petkov PM, Hurston E, Shafritz DA. Liver regeneration and alpha-fetoprotein messenger RNA expression in the retrorsine model for hepatocyte transplantation. Cancer Research 1998;58,24:5825-5834.

37. [37]. Tai WC, Hu TH, Wang JH, Hung CH, Lu SN, Changchien CS, Lee CM. Clinical implications of alpha-fetoprotein in chronic hepatitis C. J Formos Med Assoc. 2009;108,3:210-218.